ReviewInternational journal of colorectal disease2023
Current status and prospect of immunotherapy for colorectal cancer.
Review in International journal of colorectal disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Microsatellite Stable Colorectal Tumours in Patients with Lynch Syndrome: A Case Report and Systematic Review Analysing Clinical Features and Implications for Immunotherapy.Journal of gastrointestinal cancer · 2025Pooled it
- Origin dictates function: The dual roles of exosomes derived from diverse origins in the onset and progression of colorectal cancer (Review).Oncology reports · 2026Review
- Mechanism of Icariin induces mitochondrial-mediated apoptosis by Wnt/β-catenin signaling pathway in colorectal cancer.Frontiers in pharmacology · 2026Article
- Impact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation.Clinical & experimental metastasis · 2025Article
- Analysis of antinuclear antibody pattern distribution and correlation in patients with colorectal cancer.World journal of gastrointestinal surgery · 2025Article
- MRI-based radiomics for preoperative T-staging of rectal cancer: a retrospective analysis.International journal of colorectal disease · 2025Article
- Expression significance of biomarker MORC4 in colorectal cancer patients and its relationship with pathological features and prognosis.World journal of gastrointestinal oncology · 2025Article
- Anti-Cancer and Pro-Immune Effects of Lauric Acid on Colorectal Cancer Cells.International journal of molecular sciences · 2025Article
- Crosstalk between non-coding RNAs and programmed cell death in colorectal cancer: implications for targeted therapy.Epigenetics & chromatin · 2025Review
- Immunotherapy against colorectal cancer via delivery of anti-PD-L1 nanobody mRNA.eGastroenterology · 2025Article
- Melittin Inhibits Colorectal Cancer Growth and Metastasis by Ac-Tivating the Mitochondrial Apoptotic Pathway and Suppressing Epithelial-Mesenchymal Transition and Angiogenesis.International journal of molecular sciences · 2024Article
- Impact of perioperative prognostic nutritional index changes on the survival of patients with stage II/III colorectal cancer.Annals of gastroenterological surgery · 2024Article
- SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.Cancer communications (London, England) · 2024Article
- Hawthorn Proanthocyanidin Extract Inhibits Colorectal Carcinoma Metastasis by Targeting the Epithelial-Mesenchymal Transition Process and Wnt/β-Catenin Signaling Pathway.Foods (Basel, Switzerland) · 2024Article
- Article
- The role of ferroptosis in colorectal cancer and its potential synergy with immunotherapy.Frontiers in immunology · 2024Review
- Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal cancer is the most common gastrointestinal tumor in China. While significant progress has been achieved in traditional chemotherapy, radiotherapy, and targeted therapy, the prognosis of advanced colorectal cancer is poor, and the five-year survival rate is unsatisfactory. There is an urgent need to explore new treatment modalities. In this review, we examined the latest progress of colorectal cancer immunotherapy and discussed its future prospects.
methodsWe conducted a literature review to sort out the current status of immunotherapy for different types of colorectal cancer and discussed potential combination therapy options. Results Subsequent line therapy, first-line therapy and neoadjuvant therapy for MSI-H/dMMR colorectal cancer are discussed. In addition, combination therapy options for patients with MSS/pMMR colorectal cancer are presented. Finally, current valuable biomarkers for immunotherapy are highlighted.
resultsSubsequent line therapy, first-line therapy and neoadjuvant therapy for MSI-H/dMMR colorectal cancer are discussed. In addition, combination therapy options for patients with MSS/pMMR colorectal cancer are presented. Finally, current valuable biomarkers for immunotherapy are highlighted.
conclusionThis review discussed the current status of immunotherapy for different types of colorectal cancer and biomarkers for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.